Case report: persistent anemia after eculizumab in paroxysmal nocturnal hemoglobinuria: non-dominantly active intravascular hemolysis

Key Points

• To investigate the relationship between persistent anemia and subclinical intravascular hemolysis in PNH patients post-eculizumab treatment.
• Case report analysis of a patient with PNH
• Monitoring patient response to C5 inhibitor therapy
• Assessment of hemolysis activity and anemia
• Evaluation of management options with proximal complement inhibitors
• Persistent anemia observed after eculizumab therapy
• Association with subclinical intravascular hemolysis was suggested
• Proximal complement inhibitors like iptacopan may improve management.